Insider Selling: Privia Health Group, Inc. (NASDAQ:PRVA) CEO Sells $225,073.98 in Stock

Privia Health Group, Inc. (NASDAQ:PRVA) CEO Parth Mehrotra sold 12,219 shares of the business’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total transaction of $225,073.98. Following the sale, the chief executive officer now directly owns 261,640 shares of the company’s stock, valued at $4,819,408.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Privia Health Group Stock Up 1.8 %

Privia Health Group stock opened at $18.74 on Friday. The stock has a 50-day moving average price of $19.62 and a 200 day moving average price of $21.12. The company has a market capitalization of $2.22 billion, a price-to-earnings ratio of 98.64, a price-to-earnings-growth ratio of 2.56 and a beta of 0.81. Privia Health Group, Inc. has a 52 week low of $17.54 and a 52 week high of $30.15.

Privia Health Group (NASDAQ:PRVA) last issued its earnings results on Tuesday, February 27th. The company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). The business had revenue of $440.80 million for the quarter, compared to analysts’ expectations of $425.81 million. Privia Health Group had a return on equity of 3.97% and a net margin of 1.39%. The company’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same period last year, the business earned $0.14 EPS. Research analysts anticipate that Privia Health Group, Inc. will post 0.26 EPS for the current fiscal year.

Institutional Trading of Privia Health Group

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Park Place Capital Corp grew its stake in shares of Privia Health Group by 115.4% during the 1st quarter. Park Place Capital Corp now owns 2,492 shares of the company’s stock worth $49,000 after purchasing an additional 1,335 shares during the period. Benjamin Edwards Inc. boosted its position in Privia Health Group by 44.9% during the fourth quarter. Benjamin Edwards Inc. now owns 3,239 shares of the company’s stock worth $75,000 after purchasing an additional 1,003 shares in the last quarter. Covestor Ltd lifted its position in shares of Privia Health Group by 8.3% during the 3rd quarter. Covestor Ltd now owns 6,703 shares of the company’s stock valued at $154,000 after buying an additional 514 shares in the last quarter. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Privia Health Group in the fourth quarter valued at about $158,000. Finally, International Assets Investment Management LLC increased its stake in Privia Health Group by 2,721.7% during the 4th quarter. International Assets Investment Management LLC now owns 7,139 shares of the company’s stock worth $164,000 after buying an additional 6,886 shares in the last quarter. 94.48% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PRVA has been the subject of several research reports. Bank of America cut Privia Health Group from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $27.00 to $21.00 in a report on Thursday, February 22nd. Citigroup assumed coverage on shares of Privia Health Group in a research note on Monday, April 22nd. They set a “buy” rating and a $25.00 price objective on the stock. Truist Financial lowered their target price on Privia Health Group from $32.00 to $28.00 and set a “buy” rating for the company in a report on Thursday, February 29th. JPMorgan Chase & Co. cut their price target on Privia Health Group from $38.00 to $30.00 and set an “overweight” rating on the stock in a report on Wednesday, March 6th. Finally, Stifel Nicolaus decreased their price objective on Privia Health Group from $28.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $27.62.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.